ASIT biotech announced the achievement of new clinical and corporate development milestones. The confirmatory phase III clinical study with gp-ASIT+™ is on track with the last treatment visit of the last patient reached before the start of the pollen season. A total of 651 patients with moderate to severe allergic rhinitis have been treated, above the initial target of 624 patients. This high number of patients has been reached earlier than planned, that reflects the strong interest for the short-course immunotherapy developed by ASIT biotech and provides a solid sample for statistical analysis. Safety data were followed up by an independent Data Safety Monitoring Board (DSMB) on a weekly basis during this treatment period. The DSMB always recommended to continue the study without modification. Patients monitoring and data collection in 70 participating European centers is ensured using performant electronic diaries. The whole process during the entire pollen season will be under the tight control of the ASIT biotech clinical team and the dedicated CRO, ICON Plc., with the aim of obtaining primary efficacy results by end-2019 as expected.